Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the “Company” or “Inspira Technologies”), a company aiming to revolutionize acute respiratory care by empowering breathing without lungs, is proud to announce the unveiling of its INSPIRA ART line at the Extracorporeal Life Support Organization (ELSO) Conference in Seattle, WA.
The INSPIRA ART medical device line includes the INSPIRA™ ART100 a cardio-pulmonary bypass (CPB) device designed for patients undergoing CPB procedures as well as the INSPIRA™ ART500 device that represents a significant breakthrough in healthcare, potentially offering highly effective treatment for the 20 million patients that face severe breathing problems each year. The INSPIRA ART500 is being designed to provide acute respiratory support with the intention to become a new procedure for patients who may require legacy mechanical ventilation.
INSPIRA ART100 is estimated to receive U.S. Food and Drug Administration (FDA) clearance in the first half of 2024. Inspira is currently working on plans to make INSPIRA ART100 available in the United States. The Company has recently entered into a collaboration with Perfusion Solution, Inc., a leading U.S. based company that provides a platform of advanced medical devices, training and staffing to leading U.S. hospitals.
The ELSO conference is a global gathering of experts in healthcare, research, and industry players. ELSO is dedicated to improving a special type of life support called extracorporeal life support, which involves using external devices to support patients with severe breathing and/or heart problems.
Inspira will be available at booth #315 at the 34th annual ELSO conference. Inspira will be introducing its new INSPIRA ART device line, revealing the INSPIRA ART100 device at ELSO, which marks a significant achievement by its team of experts. Inspira’s presentation of its product is a significant step forward, highlighting its commitment to creating products for critical patient care or patients undergoing CPB.
